REG - OptiBiotix Health - Half-year Report <Origin Href="QuoteRef">OPTIO.L</Origin> - Part 2

OptiBiotix HealthAnnouncement

30/08/2017 07:06

- Part 2: For the preceding part double click  ID:nRSd2269Pa 

         
                                                                                  ──────                           ──────                           ──────                           
 Cash and cash equivalents at end of year                                         1,923,018                        3,556,264                        3,115,366                        
                                                                                  ══════                           ══════                           ══════                           
 
 
Notes to the Half Yearly Report 
 
For the period to 31 May 2017 
 
1.    General Information 
 
Optibiotix Health Plc is a company incorporated and domiciled in England and
Wales. The company's offices are in York. The company is listed on the AIM
market of the London Stock Exchange (ticker: OPTI). 
 
The financial information set out in this Half Yearly report does not
constitute statutory accounts as defined in Section 434 of the Companies Act
2006.  The group's statutory financial statements for the year ended 30
November 2016, prepared under International Financial Reporting Standards
("IFRS"), have been filed with the Registrar of Companies.  The auditor's
report on those financial statements was unqualified and did not contain
statements under Sections 498(2) and 498 (3) of the Companies Act 2006. 
 
Copies of the annual statutory accounts and the Half Yearly report can be
found on the Company's website at http://www.optibiotix.com/. 
 
2.    Basis of preparation and significant accounting policies 
 
This Half Yearly report has been prepared using the historical cost
convention, on a going concern basis and in accordance with International
Financial Reporting Standards ("IFRS") as adopted by the European Union, using
accounting policies which are consistent with those set out in the financial
statements for the year ended 30 November 2016. 
 
New and amended standards adopted by the group 
 
There are no IFRSs or IFRIC interpretations that are effective for the first
time in this financial period that would be expected to have a material impact
on the group. 
 
3.    Segmental Reporting 
 
In the opinion of the directors, the group has one class of business, being
that of research and development. The group's primary reporting format is
determined by the geographical segment according to the location of its
establishments. There is currently only one geographic reporting segment,
which is the UK. All costs are derived from the single segment. 
 
4.    Earnings per Share 
 
Basic earnings per share is calculated by dividing the earnings attributable
shareholders by the weighted average number of ordinary shares outstanding
during the period. 
 
Reconciliations are set out below: 
 
                                                 6 Months to31 May 2017Unaudited  6 Months to 31 May 2016Unaudited  Year to 30 November 2016Audited  
                                                                                                                                                     
 Basic and diluted EPS                                                                                                                               
                                                                                                                                                     
 Earnings attributable to ordinary shareholders  3,132,001                        (615,243)                         (1,297,871)                      
                                                                                                                                                     
 Weighted average number of shares               78,517,954                       77,261,548                        77,683,891                       
                                                                                                                                                     
 Earnings (Loss) per-share - pence               3.97p                            (0..80)p                          (1.67)p                          
                                                 ═════                            ═════                             ═════                            
 Earnings attributable to ordinary                                                                                                                   
 Shares before Profit on investment                                                                                                                  
 revaluation                                     (984,285)                        (615,243)                         (1,297,871)                      
                                                                                                                                                     
 (Loss) per-share - pence                        (1.3)p                           (0..80)p                          (1.67)p                          
                                                 ═════                            ═════                             ═════                            
 
 
Basic and diluted earnings per share are the same, since where a loss is
incurred the effect of outstanding share options and warrants is considered
anti-dilutive and is ignored for the purpose of the loss per share
calculation. As at 31 May 2017 there were 10,011,904 outstanding share options
and 1,572,310 outstanding share warrants. 
 
5.   Investments in associate undertakings 
 
On 4 April 2017 the group reduced its shareholding in its subsidiary,
SkinBiotix Limited, from 52% to 41.9% as a result of their listing on the AIM
stock exchange and is now accounted for as an associate under the equity
accounting method. 
 
 Company                           
                        £          
 Cost                              
 At 30 November 2016    -          
 Additions              4,398,539  
                        ═══════    
 Carrying amount                   
 At 31 May 2017         4,398,539  
                        ══════     
 
 
6.   Share Capital 
 
Issued share capital comprises: 
 
                                             6 months to 31 May 2017Unaudited  6 months to 31 May 2016Unaudited  Year to 30 November2016Audited  
                                             £                                 £                                 £                               
                                                                                                                                                 
 Ordinary shares of 2p each78,543,318        1,570,866                         1,559,731                         1,563,286                       
 Deferred shares of 19p each26,001,739       4,940,330                         4,940,330                         4,940,330                       
 Deferred shares of .90p each63,373,961      570,366                           570,366                           570,366                         
 Deferred shares of 0.09p each135,587,293    122,028                           122,028                           122,028                         
                                             ───────                           ───────                           ───────                         
                                             7,203,590                         7,192,455                         7,196,010                       
                                             ═══════                           ═══════                           ═══════                         
 
 
During the six months to 31 May 2017 the company issued ordinary shares of
£0.02 each listed, exercised at a price of £0.08 per share in the capital of
the company following the exercise of warrants: 
 
 Date issued  Number   
                       
 04/01/2017   29,375   
 13/01/2017   333,333  
 16/02/2017   16,351   
                       
              ───────  
              379,059  
              ═══════  
 
 
7.   Post balance sheet events 
 
On 6 July 2017 directors, Per Rehné and Christina Wood were each granted
500,000 options. the options have an exercise price of 69.5p per share and an
expiration date of 23 June 2027. 
 
This information is provided by RNS
The company news service from the London Stock Exchange